HepCBC is seeking individual patient input for our submission to the federal government for the first INTERFERON-FREE drug combo for GENOTYPE 4, AbbVie’s “2D-GT4”.

ADD YOUR VOICE! We will be accepting input from anyone affected by hepatitis C (ALL GENOTYPES, not only Genotype 4) between Friday, Sept. 11 and midnight on Thursday, Sept. 25, 2015 through this confidential online form: 
PATIENT INPUT FORM for AbbVie 2D-GT4 

Free WEBINAR about AbbVie 2D-GT4 available Monday, September 21st from 8 am – 9 am Pacific Time. Hosted by Canadian Treatment Action Council (CTAC). 
REGISTER HERE.

EVER WONDER WHAT WE DO WITH YOUR INPUT? View all of our Patient Group Submissions since 2011 HERE!

FURTHER INFORMATION about this new treatment: the great links below about AbbVie 2D-GT4 put together by NATAP in the USA (Thanks, NATAP!):

  Abbvie GT4 FDA Label/PI – (07/28/15)
 
FDA approves Technivie (Abbvie 2D) for treatment of chronic hepatitis C genotype 4 – (07/28/15)
 
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial – (06/19/15) published
 
EASL/2014: RESULTS FROM THE PHASE 2 PEARL-I STUDY: INTERFERON-FREE REGIMENS OF ABT-450/r + ABT-267 WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 4 INFECTION – (04/16/14)
 
AASLD/2014: Interferon-Free Regimens of Ombitasvir and ABT-450/r With or Without Ribavirin in Patients With HCV Genotype 4 Infection: PEARL-I Study Results – (12/01/14)
 
EASL: A Randomized, Open-Label Study to Evaluate Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Infection and Cirrhosis (AGATE-I) – (04/23/15)
 
EASL: An Open-Label Study to Evaluate the Efficacy and Safety of Co-Formulated Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults with Chronic HCV Genotype 4 Infection in Egypt (AGATE-II) – (04/24/15)